Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00358943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary and study completion dates: Jan 31, 2030 to Jan 31, 2034
Study sites: 63 to 221
v23
MinorPublications: 6 to 8v22
MinorPrimary and study completion dates: Jan 2030 to Jan 31, 2030v21
MinorStudy sites: 1 to 63v20
Minor2 versionsRe-verified since Aug 26, 2014, no change to tracked fieldsv18-v19
MinorStudy description shortened, about 47 wordsv17
MinorRe-verified, no change to tracked fieldsv16
MinorEnrollment target: 12000
Primary and study completion dates: Jan 2030
v15
MinorStudy description shortened, about 1 wordv14
Minor4 versionsRe-verified since Jul 30, 2009, no change to tracked fieldsv10-v13
MinorEnrollment target: 99999 to not statedv9
MinorEnrollment target: 99999v8
MinorRe-verified, no change to tracked fieldsv7
MinorStudy Status, Study Design, Eligibilityv6
MinorEligibility criteria expanded, about 1 word
Study description expanded, about 1 word
Study title expanded, about 2 words
v5
MinorStart date: Nov 2001 to Apr 1991v4
MinorStudy description revisedv3
MinorStudy description shortened, about 290 words
Study site revised
v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Gaucher disease population.
* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.
Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.